Microbot Medical

Microbot Medical

Microbot Medical was established in 2010 and is led by Chairman, CEO and President Harel Gadot from its headquarters in Braintree, Massachusetts. The firm is not a family office or investment manager; it is a publicly traded medical device company (Nasdaq: MBOT) focused on developing single-use robotic systems. Unlike its dominant capital-intensive rivals, the firm's entire value proposition hinges on disposable hardware and a pricing model targeting ambulatory surgery centers and catheterization labs that cannot afford the multi-million-dollar systems sold by Intuitive Surgical. The company's sole platform, the LIBERTY Endovascular Robotic System, is designed to enable remote, precise manipulation of guidewires and catheters during vascular interventional procedures. Microbot has targeted interventional cardiology and peripheral vascular disease as initial applications. The firm achieved a regulatory breakthrough in August 2024 when it received its first FDA 510(k) clearance for LIBERTY, signaling it can begin commercialization in the United States. Pre-commercialization clinical work was conducted at sites including Baptist Hospital in Miami. The firm has also completed a pivotal human clinical trial, and its development path included a co-development agreement with Stryker Corporation for a separate device that was later terminated. Microbot Medical operates with a lean corporate structure and no disclosed revenue stream; its funding model is entirely public market equity. The firm's professional headcount is not disclosed. In May 2024, the company appointed a U.S.-based reimbursement and commercial strategy consultant to prepare for the LIBERTY launch. It has also engaged in pre-clinical studies with leading interventional radiologists in New York. The firm's governance includes Gadot's dual role and a board typical of a publicly listed med-tech startup. Structurally, Microbot Medical is an outlier in the robotics space: it does not sell a capital equipment system. Instead, it intends to sell a single-use disposable cassette and remote controller per procedure, eliminating the hospital's upfront capital outlay and the need for a dedicated robotics suite. This disposable razor-and-blades model — where the razor is cheap and the blade is proprietary — is a direct counter-strategy to the installed-base moat held by the trillion-dollar surgical robotics incumbents.